C4 Therapeutics, Inc.
CCCC
$2.53
-$0.08-3.07%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 1.15% | 23.87% | -40.16% | -39.23% | 37.53% |
| Total Depreciation and Amortization | 34.87% | -5.00% | 8.60% | -1.34% | 0.00% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -4.66% | -26.77% | -3.88% | 41.47% | -0.19% |
| Change in Net Operating Assets | 152.45% | -286.15% | 182.48% | -253.37% | 74.80% |
| Cash from Operations | 63.78% | -85.62% | 25.70% | -385.18% | 72.55% |
| Capital Expenditure | -- | -- | -69.23% | 106.60% | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 34.27% | 113.12% | 9,071.81% | 101.29% | 78.45% |
| Cash from Investing | 33.63% | 113.06% | 8,338.27% | 101.38% | 78.08% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -98.92% | 7,525.19% | -99.61% |
| Repurchase of Common Stock | 100.00% | -- | 100.00% | -- | 100.00% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -100.00% | 10,800.00% | -99.66% | -- | -100.00% |
| Cash from Financing | 100.00% | -141.07% | -98.93% | 7,682.22% | -99.61% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 738.71% | -1.35% | 69.18% | 18.62% | 55.20% |